
A promising therapy has been discovered that targets the protein BMP5/7 and slows down or stops the progress of Parkinson's disease.
The study conducted at Ben-Gurion University of the Negev is published in the clinical neurology journal Brain.
Advertisement
‘Reduced BMP5/7 signaling in neurons contributes to Parkinson’s disease progression. In advanced form Parkinson’s disease, therapies that target the protein BMP5/7 and slow down or stop the progress of Parkinson’s disease.’
Read More..
Tweet it Now
Read More..
Parkinson's disease affects over one million people in U.S. and 10 million worldwide. Parkinson's disease causes symptoms like tremors and severe movement impairment due to progressive degeneration of dopaminergic neurons.
The protein present in all human brains called 'alpha-synuclein' misfolds and forms toxic clumps in the cells found to be the main cause of the Parkinson's disease. Current therapies for Parkinson's improve symptoms but they are not effective in the advanced stage of illness and they do not slow or cure the disease.
The researchers discovered that BMP5/7 signaling in neurons was significantly reduced in dopamine-producing brain cells, which can contribute to Parkinson's disease progression.
Dr. Claude Brodski, M.D., head of the BGU's Laboratory for Molecular Neuroscience said, "Indeed, we found that BMP5/7 treatment can, in a Parkinson's disease mouse model, efficiently prevent movement impairments caused by the accumulation of alpha-synuclein and reverse the loss of dopamine-producing brain cells. These findings are very promising, since they suggest that BMP5/7 could slow or stop Parkinson's disease progression. Currently, we are focusing all our efforts on bringing our discovery closer to clinical application."
Dr. Galit Mazooz Perlmuter, senior vice president of business development, bio-pharma at BGN Technologies said that there is a need for new therapies for the treatment of Parkinson's disease specifically for the treatment of advanced stages of the disease.
Dr. Galit Mazooz Perlmuter said, "Dr. Brodski's findings, although still in their early stages, offer a disease-modified drug target that will address this devastating condition. We are now seeking an industry partner for further development of this patent pending invention."
Source: Medindia
Advertisement
The researchers discovered that BMP5/7 signaling in neurons was significantly reduced in dopamine-producing brain cells, which can contribute to Parkinson's disease progression.
Dr. Claude Brodski, M.D., head of the BGU's Laboratory for Molecular Neuroscience said, "Indeed, we found that BMP5/7 treatment can, in a Parkinson's disease mouse model, efficiently prevent movement impairments caused by the accumulation of alpha-synuclein and reverse the loss of dopamine-producing brain cells. These findings are very promising, since they suggest that BMP5/7 could slow or stop Parkinson's disease progression. Currently, we are focusing all our efforts on bringing our discovery closer to clinical application."
Dr. Galit Mazooz Perlmuter, senior vice president of business development, bio-pharma at BGN Technologies said that there is a need for new therapies for the treatment of Parkinson's disease specifically for the treatment of advanced stages of the disease.
Dr. Galit Mazooz Perlmuter said, "Dr. Brodski's findings, although still in their early stages, offer a disease-modified drug target that will address this devastating condition. We are now seeking an industry partner for further development of this patent pending invention."
Source: Medindia
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Research News

New study sheds light on the intrinsic, yet often overlooked, role of sleep preparation as a hardwired survival strategy.

Microgravity-induced bone loss in space, can be reduced by systemic delivery of NELL-1, a protein required for bone growth and its maintenance.

Researchers establish connections between Alzheimer's-linked genetic alterations and the functioning of brain cells.

Team at NeuroRestore introduces a groundbreaking gene therapy that has effectively promoted nerve regrowth and reconnection, post spinal cord injury.

Scientists aim to pinpoint particular functional pathways affected by these bacteria that may have an impact on skeletal health.